Last update 21 Nov 2024
Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Therapeutic vaccine, Dendritic cell vaccine |
Synonyms- |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators), HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer After Neoadjuvant Therapy
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)
100 Clinical Results associated with Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)
Login to view more data
100 Translational Medicine associated with Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)
Login to view more data
100 Patents (Medical) associated with Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)
Login to view more data
100 Deals associated with Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | Phase 1 | US | 22 Aug 2023 | |
| Meningeal Neoplasms | Phase 1 | US | 22 Aug 2023 | |
| ER-low Breast cancer | Phase 1 | US | 26 Aug 2022 | |
| HER2-negative breast cancer | Phase 1 | US | 26 Aug 2022 | |
| Triple Negative Breast Cancer | Phase 1 | US | 26 Aug 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free